Shaanxi Kanghui Pharmaceutical Co., Ltd. Stock

Equities

603139

CNE100002XT3

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
13.94 CNY +0.65% Intraday chart for Shaanxi Kanghui Pharmaceutical Co., Ltd. +10.90% -25.73%

Financials

Sales 2022 492M 67.89M 93.07M Sales 2023 673M 92.96M 127M Capitalization 1.87B 259M 355M
Net income 2022 -63M -8.7M -11.93M Net income 2023 -26M -3.59M -4.92M EV / Sales 2022 4.24 x
Net Debt 2022 313M 43.24M 59.28M Net Debt 2023 318M 43.98M 60.3M EV / Sales 2023 3.26 x
P/E ratio 2022
-28.2 x
P/E ratio 2023
-72.2 x
Employees 828
Yield 2022 *
-
Yield 2023
-
Free-Float 39.72%
More Fundamentals * Assessed data
Dynamic Chart
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback MT
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sichuan Chunsheng Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 56.795265 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. completed the acquisition of an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership). CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. agreed to acquire an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership) for CNY 30 million. CI
More news
1 day+0.65%
1 week+10.90%
Current month-8.95%
1 month-8.95%
3 months-15.52%
6 months-30.96%
Current year-25.73%
More quotes
1 week
12.89
Extreme 12.89
14.22
1 month
12.03
Extreme 12.03
17.23
Current year
8.81
Extreme 8.81
19.72
1 year
8.81
Extreme 8.81
21.60
3 years
8.81
Extreme 8.81
28.20
5 years
8.81
Extreme 8.81
28.20
10 years
8.81
Extreme 8.81
44.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 98-12-31
Director of Finance/CFO 37 18-12-10
Director/Board Member 48 -
Members of the board TitleAgeSince
Director/Board Member 63 09-12-10
Chief Executive Officer 64 98-12-31
Director/Board Member 60 19-12-10
More insiders
Date Price Change Volume
24-04-30 13.94 +0.65% 1,445,100
24-04-29 13.85 +3.67% 1,692,500
24-04-26 13.36 -0.37% 1,436,800
24-04-25 13.41 +1.82% 1,381,900
24-04-24 13.17 +1.31% 1,517,078

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. is principally engaged in research and development, manufacture and sales of Chinese patent medicines. The Company's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The Company distributes its products just within China domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 603139 Stock